| Terminated | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574 | Biomea Fusion Inc. | Phase 1 |
| Unknown | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary NCT05240690 | Zhou Fuxiang | Phase 1 |
| Unknown | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancre NCT05088889 | Sheba Medical Center | Phase 1 |
| Recruiting | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042 | General Oncology, Inc. | Phase 1 |
| Unknown | Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer NCT04377048 | National Taiwan University Hospital | Phase 2 |
| Unknown | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites NCT04267575 | Jerome Canady, M.D. | N/A |
| Active Not Recruiting | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer NCT03825289 | University of Utah | Phase 1 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Completed | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer NCT03412799 | Panbela Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | TAS102 in Combination With NAL-IRI in Advanced GI Cancers NCT03368963 | Emory University | Phase 1 / Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Completed | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer NCT03095781 | Emory University | Phase 1 |
| Completed | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid NCT03087591 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients NCT03222258 | Seoul National University Hospital | — |
| Completed | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic NCT02896907 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Completed | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer NCT02620865 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Withdrawn | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Tr NCT02048943 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or NCT02227940 | Roswell Park Cancer Institute | Phase 1 |
| Completed | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer NCT02333188 | University of Chicago | Phase 1 |
| Withdrawn | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian NCT01927393 | City of Hope Medical Center | N/A |
| Completed | Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer NCT02307539 | City of Hope Medical Center | N/A |
| Completed | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer NCT02178436 | Mohammed Najeeb Al Hallak | Phase 1 / Phase 2 |
| Withdrawn | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liv NCT01741597 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancr NCT02414100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Completed | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previou NCT02050178 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Completed | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated S NCT02005315 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Completed | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer NCT01924260 | Edward Kim | Phase 1 |
| Completed | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT01839981 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA NCT01893801 | Pancreatic Cancer Research Team | Phase 1 / Phase 2 |
| Completed | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer NCT01835041 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer NCT01893294 | Mayo Clinic | Phase 1 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer NCT01666730 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer NCT01851174 | Western Regional Medical Center | Phase 2 |
| Completed | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors NCT01525082 | Shaheen Shagufta | Phase 2 |
| Completed | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects Wit NCT01647828 | OncoMed Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Pa NCT01658943 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer NCT01473940 | Northwestern University | Phase 1 |
| Completed | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastati NCT01497392 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointest NCT01643499 | University of Chicago | Phase 1 |
| Completed | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Can NCT01537107 | Mayo Clinic | Phase 1 |
| Completed | VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Canc NCT01486329 | Vaximm GmbH | Phase 1 |
| Completed | Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer NCT01488552 | Pancreatic Cancer Research Team | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer NCT01191684 | City of Hope Medical Center | Phase 1 |
| Terminated | Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca NCT01555489 | Thomas Jefferson University | Phase 2 |
| Completed | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer NCT01453153 | Halozyme Therapeutics | Phase 1 / Phase 2 |
| Terminated | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pan NCT01280058 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer NCT01227018 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT01222689 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer NCT01232829 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer NCT01195415 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tum NCT01145456 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Ca NCT00981162 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer NCT00735917 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer NCT00577889 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Tre NCT00617708 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer NCT00474812 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors NCT00462553 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer NCT00416793 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With NCT00397787 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pan NCT01534637 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer P NCT00383760 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer NCT00331682 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer NCT00114244 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00095966 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer NCT00085371 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pan NCT00091026 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT00088894 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00075647 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer NCT00052689 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Ad NCT00047307 | National Cancer Institute (NCI) | Phase 1 |
| Completed | UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer NCT00039403 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer NCT00031694 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer NCT00028834 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer NCT00003531 | Burzynski Research Institute | Phase 2 |
| Withdrawn | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic P NCT02575508 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |